Meditope Nabs $3.6M to Turn MAbs into 'Legos'
Start-up Meditope Biosciences Inc. tucked $3.6 million under its belt in a Series A funded by angel investors to advance its monoclonal antibody (MAb) linker technology. The Los Angeles-based biotech is advancing cancer therapeutics discovered at City of Hope, a National Cancer Institute-designated Comprehensive Cancer Center in Duarte, Calif.
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Sign up for Perspectives FREE e-mail newsletter